NHS England agrees to funding Ilaris for children with PFS

2 March 2020

NHS England said on Saturday that it will fund a life-changing treatment for people with rare conditions causing repeated bouts of fever, joint pain and swelling.

Periodic fever syndromes (PFS) are a group of rare genetic conditions where the person’s immune system overreacts, resulting in frequent inflammation ‘flares’, involving chest or joint pains, headaches, mouth ulcers and skin rash.

On World Rare Diseases Day (Saturday February 29) the National Health Service (NHS) confirmed a deal has been struck for canakinumab, which modifies the immune system, turning off the inflammation process, significantly reducing the number of ‘flares’ children and adults experience.

The drug, which is approved in a number of indications, is marketed by Swiss pharma giant Novartis (NOVN: VX) under the trade name Ilaris and generated global sales for the company of $671 million in 2019, a year-on-year increase of 21%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK